Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0S4OP
|
|||
| Drug Name |
PMID28394193-Compound-28
|
|||
| Drug Type |
Small molecular drug
|
|||
| Company |
GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C33H38N6O2
|
|||
| Canonical SMILES |
CC1=CC2=C(CNC(=O)C3=C4C(=CN(C4=CC(=C3)C5=CN=C(C=C5)N6CCNCC6)C(C)C)CC=CCC2)C(=O)N1
|
|||
| InChI |
1S/C33H38N6O2/c1-21(2)39-20-25-8-6-4-5-7-23-15-22(3)37-33(41)28(23)19-36-32(40)27-16-26(17-29(39)31(25)27)24-9-10-30(35-18-24)38-13-11-34-12-14-38/h4,6,9-10,15-18,20-21,34H,5,7-8,11-14,19H2,1-3H3,(H,36,40)(H,37,41)/b6-4+
|
|||
| InChIKey |
GMAFAVDEQFGQCC-GQCTYLIASA-N
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Enhancer of zeste homolog 2 (EZH2) | Target Info | Inhibitor | [1] |
| Target's Patent Info | Enhancer of zeste homolog 2 (EZH2) | Target's Patent Info | [1] | |
| KEGG Pathway | MicroRNAs in cancer | |||
| NetPath Pathway | IL2 Signaling Pathway | |||
| Reactome | PRC2 methylates histones and DNA | |||
| Oxidative Stress Induced Senescence | ||||
| PKMTs methylate histone lysines | ||||
| WikiPathways | Interactome of polycomb repressive complex 2 (PRC2) | |||
| Endoderm Differentiation | ||||
| Integrated Pancreatic Cancer Pathway | ||||
| Histone Modifications | ||||
| Cell Differentiation - meta | ||||
| miRs in Muscle Cell Differentiation | ||||
| miR-targeted genes in muscle cell - TarBase | ||||
| miR-targeted genes in lymphocytes - TarBase | ||||
| miR-targeted genes in epithelium - TarBase | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | EZH2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jul;27(7):797-813. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.